Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-09-25
2010-11-09
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S178100
Reexamination Certificate
active
07829677
ABSTRACT:
The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia.
REFERENCES:
patent: 5286647 (1994-02-01), Handley et al.
patent: 2002/0098581 (2002-07-01), Glassy et al.
patent: WO-97-39774 (1997-10-01), None
patent: WO-99-43815 (1999-09-01), None
Stanton, P et al, 1994, Br J Cancer, 70: 427-433.
Iehle, C et al, 1999, J Steroid Biochem Mol Biol, 68: 189-195.
Geng et al, Cellular and molecular immunology (China), 2006, 3 (6), p. 439-43.
Rudikoff et al, PNAS, USA, 1982, 79: 1979.
Glassy, M.C. et al., “Requirements for human antibody cocktails for oncology,” Exp. Op. Biol. Ther. 5(10):1333-1338 (2005).
Mukerjee, S. et al., “Co-expression of tumor antigens and their modulation by pleiotrophic modifiers enhance targeting of human monoclonal antibodies to pancreatic carcinoma,” Human Antibodies 9:9-22 (1999).
Mukerjee, S. et al., “Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells,” Hybridoma 17(2):133-142 (1998).
Yano, Y. et al., “Immunohistological Characterization of Human Monoclonal Antibody Against Lung Cancer,” J. Surgical Oncol. 39:108-113 (1988).
Buskens, C. et al., “Adenocarcinomas of the Gastro-Esophageal Junction: A Comparative Study of the Gastric Cardia and the Esophagus with Respect to Cyclooxygenase-2 Expression,” Digestive Disease Week Abstracts and Itinerary Planner, vol. 2003, abstract No. 850, 2003, e-file.
Gura, T., “Systems for Identifiyng New Drugs Are Often Faulty,” Science vol. 278:1041-1042, Nov. 7, 1997.
Karaczyn, A. et al., “The Octapeptidic End of the C-Terminal Tail of Histone H2A Is Cleaved Off in Cells Exposed to Carcinogenic Nickel (II),” Chem. Res. Toxicol. 16:1555-1559 (2003).
Martin, A. and Weber, B.L., “Genetic and Hormonal Risk Factors in Breast Cancer,” J. of the National Cancer Inst., vol. 92, No. 14, Jul. 19, 2000.
Mylonas, M. et al., “An extremely stable Ni(II) complex derived from the hydrolytic cleavage of the C-terminal tail of histone H2A,” J. Inorg. Biochem. 99:637-643 (2005).
White, C.A., et al., “Antibody-Targeted Immunotherapy for Treatment of Malignancy,” Annu. Rev. Med. 2001, 52:125-45.
Oct. 2005, “Temporary protocol of treatment: Trastuzumab (Herceptin®) in adjuvant conditions,” Institu National de Cancer and Agence francaise de securite sanitaire des produits de sante, www.e-cancer.fr/medias/pttdefeng2710.pdf, Web site. Ref cannot be published.
Bowie, J.U. et al., “Deciphering the Message in Protein Sequences: Tolerance in Amino Acid Substitutions,” Science 257:1306-1310 (1990).
Burgess, W.H. et al., “Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-Binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” J. Cell. Biol. 111:2129-2138 (1990).
Gillies, S.D. and Wesolowski, J.S., “Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities,” Human Antibodies and Hybridomas 1(1):47-54 (1990).
Paul, W.E., 3rded. 1993, Fundamental Immunology, p. 242.
Tao, M.H. and Morrison, S.L., “Studies of Agylcosylated Chimeric Mouse-Human IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region,” J. Immunol. 143(8):2595-2601 (1989).
Chakrabarti Subhra
Glassy Mark C.
Mukerjee Sonjoy
Davis Minh-Tam
Helms Larry R.
Shantha West, Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Antibodies that recognize hyperproliferative cells and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that recognize hyperproliferative cells and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that recognize hyperproliferative cells and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4250823